Key result
Low ANGPTL4 expression predicts ~100% worse disease-free survival in triple-negative breast cancer.
Why the study?
Triple-negative breast cancer patients have relatively poor clinical outcomes, and a marker predicting prognosis could help guide treatment.
Does high ANGPTL4 expression predict improved overall survival and disease-free survival in patients with triple-negative breast cancer?
Cohort (n=161)
No
Does high ANGPTL4 expression predict improved overall survival and disease-free survival in patients with triple-negative breast cancer?
Hazard Ratio: 2.005 (95% CI 1.121–3.585)
Absolute Event Rate: 56% vs 77%
p-value: p=0.019
ANGPTL4 overexpression is associated with favorable overall and disease-free survival in triple-negative breast cancer and inhibits tumor cell adhesion and migration in vitro.
ANGPTL4 expression may stratify TNBC prognosis; hypothesis-generating and requires prospective validation before any clinical role.
Background: Triple-negative breast cancer (TNBC) patients have relatively poor clinical outcomes. A marker predicting the prognosis of patients with TNBC could help guide treatment. Extensive evidence demonstrates that angiopoietin-like 4 (ANGPTL4) is involved in the regulation of cancer growth, metastasis and angiogenesis. Therefore, its role in TNBC is of interest.Methods: We tested the ANGPTL4 expression level in tumor tissues by immunohistochemistry (IHC) and detected its association with the clinical features of TNBC patients. Next, the effects and mechanisms of ANGPTL4 on TNBC cell migration and adhesion were investigated.Results: We found that ANGPTL4 overexpression was associated with favorable outcomes in TNBC patients. ANGPTL4 upregulation inhibited cell adhesion, migration and invasion in vitro. Further analyses demonstrated that the possible mechanism might involve suppression of TNBC progression by interacting with extracellular matrix-related genes.Conclusions: The present findings demonstrated that enhancement of ANGPTL4 expression might inversely correlate with TNBC progression. ANGPTL4 is a promising marker of TNBC and should be evaluated in further studies. Trial registration: Retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2020) conducted a cohort in Triple-negative breast cancer (TNBC) (n=161). Low ANGPTL4 expression vs. High ANGPTL4 expression was evaluated on Disease-free survival (5-year rate) (HR 2.005, 95% CI 1.121-3.585, p=0.019). Low ANGPTL4 expression independently predicted shorter disease-free survival in patients with triple-negative breast cancer (HR 2.005, p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: